Patents by Inventor Gary C. Look

Gary C. Look has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isoindoline compositions and methods for treating neurodegenerative disease
    Patent number: 11691947
    Abstract: Isoindoline sigma-2 receptor antagonist compounds, pharmaceutical compositions comprising such compounds, and methods for inhibiting Abeta-associated synapse loss or synaptic dysfunction in neuronal cells, modulating an Abeta-associated membrane trafficking change in neuronal cells, and treating cognitive decline associated with Abeta pathology are provided.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: July 4, 2023
    Assignee: Cognition Therapeutics, Inc.
    Inventors: Gilbert M. Rishton, Susan M. Catalano, Gary C. Look
  • COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES
    Publication number: 20220356153
    Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing the compounds and methods of using the compounds and pharmaceutical compositions for treating neurodegerative diseases, including Alzheimer's disease and cognitive decline. Methods for inhibiting synapse number decline or membrane trafficking abnormalities associated with exposure of a neuronal cell to Abeta species are also disclosed.
    Type: Application
    Filed: November 29, 2021
    Publication date: November 10, 2022
    Applicant: COGNITION THERAPEUTICS, INC.
    Inventors: Gilbert M. RISHTON, Gary C. LOOK, Susan M. CATALANO
  • Compositions for treating neurodegenerative diseases
    Patent number: 11214540
    Abstract: The present disclosure relates to novel compounds, and pharmaceutical compositions thereof, useful for treating for treating neurodegenerative diseases, including Alzheimer's disease and cognitive decline. Methods for inhibiting synapse number decline or membrane trafficking abnormalities associated with exposure of a neuronal cell to Abeta species are also disclosed.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: January 4, 2022
    Assignee: Cognition Therapeutics, Inc.
    Inventors: Gilbert M. Rishton, Gary C. Look, Susan M. Catalano
  • ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE
    Publication number: 20210009517
    Abstract: Isoindoline sigma-2 receptor antagonist compounds, pharmaceutical compositions comprising such compounds, and methods for inhibiting Abeta-associated synapse loss or synaptic dysfunction in neuronal cells, modulating an Abeta-associated membrane trafficking change in neuronal cells, and treating cognitive decline associated with Abeta pathology are provided.
    Type: Application
    Filed: February 6, 2020
    Publication date: January 14, 2021
    Applicant: COGNITION THERAPEUTICS, INC.
    Inventors: Gilbert M. Rishton, Susan M. Catalano, Gary C. Look
  • COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES
    Publication number: 20200299234
    Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing the compounds and methods of using the compounds and pharmaceutical compositions for treating neurodegenerative diseases, including Alzheimer's disease and cognitive decline. Methods for inhibiting synapse number decline or membrane trafficking abnormalities associated with exposure of a neuronal cell to Abeta species are also disclosed.
    Type: Application
    Filed: May 15, 2018
    Publication date: September 24, 2020
    Applicant: COGNITION THERAPEUTICS, INC.
    Inventors: Gilbert M. RISHTON, Gary C. LOOK, Susan M. CATALANO
  • Isoindoline compositions and methods for treating neurodegenerative disease
    Patent number: 10611728
    Abstract: Isoindoline sigma-2 receptor antagonist compounds, pharmaceutical compositions comprising such compounds, and methods for inhibiting Abeta-associated synapse loss or synaptic dysfunction in neuronal cells, modulating an Abeta-associated membrane trafficking change in neuronal cells, and treating cognitive decline associated with Abeta pathology are provided.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: April 7, 2020
    Assignee: COGNITION THERAPEUTICS, INC.
    Inventors: Gilbert M. Rishton, Susan M. Catalano, Gary C. Look
  • ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE
    Publication number: 20190210966
    Abstract: Isoindoline sigma-2 receptor antagonist compounds, pharmaceutical compositions comprising such compounds, and methods for inhibiting Abeta-associated synapse loss or synaptic dysfunction in neuronal cells, modulating an Abeta-associated membrane trafficking change in neuronal cells, and treating cognitive decline associated with Abeta pathology are provided.
    Type: Application
    Filed: December 21, 2018
    Publication date: July 11, 2019
    Applicant: Cognition Therapeutics, Inc.
    Inventors: Gilbert M. Rishton, Susan M. Catalano, Gary C. Look
  • Isoindoline compositions and methods for treating neurodegenerative disease
    Patent number: 10207991
    Abstract: Isoindoline sigma-2 receptor antagonist compounds, pharmaceutical compositions comprising such compounds, and methods for inhibiting Abeta-associated synapse loss or synaptic dysfunction in neuronal cells, modulating an Abeta-associated membrane trafficking change in neuronal cells, and treating cognitive decline associated with Abeta pathology are provided.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: February 19, 2019
    Assignee: COGNITION THERAPEUTICS, INC.
    Inventors: Gilbert M. Rishton, Susan M. Catalano, Gary C. Look
  • ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE
    Publication number: 20180086703
    Abstract: Isoindoline sigma-2 receptor antagonist compounds, pharmaceutical compositions comprising such compounds, and methods for inhibiting Abeta-associated synapse loss or synaptic dysfunction in neuronal cells, modulating an Abeta-associated membrane trafficking change in neuronal cells, and treating cognitive decline associated with Abeta pathology are provided.
    Type: Application
    Filed: September 11, 2017
    Publication date: March 29, 2018
    Inventors: Gilbert M. RISHTON, Susan M. CATALANO, Gary C. LOOK
  • Isoindoline compositions and methods for treating neurodegenerative disease
    Patent number: 9796672
    Abstract: Isoindoline sigma-2 receptor antagonist compounds, pharmaceutical compositions comprising such compounds, and methods for inhibiting Abeta-associated synapse loss or synaptic dysfunction in neuronal cells, modulating an Abeta-associated membrane trafficking change in neuronal cells, and treating cognitive decline associated with Abeta pathology are provided.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: October 24, 2017
    Assignee: COGNITION THERAPEUTICS, INC.
    Inventors: Gilbert Rishton, Susan M. Catalano, Gary C. Look
  • ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE
    Publication number: 20170144970
    Abstract: Isoindoline sigma-2 receptor antagonist compounds, pharmaceutical compositions comprising such compounds, and methods for inhibiting Abeta-associated synapse loss or synaptic dysfunction in neuronal cells, modulating an Abeta-associated membrane trafficking change in neuronal cells, and treating cognitive decline associated with Abeta pathology are provided.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 25, 2017
    Inventors: Gilbert RISHTON, Susan M. CATALANO, Gary C. LOOK
  • GGA DERIVATIVES
    Publication number: 20150133431
    Abstract: This invention relates to geranylgeranyl acetone (GGA) derivatives, pharmaceutical compositions comprising GGA derivatives and the use of GGA derivatives.
    Type: Application
    Filed: July 10, 2014
    Publication date: May 14, 2015
    Applicant: COYOTE PHARMACEUTICALS, INC.
    Inventor: Gary C. Look
  • Topoisomerase inhibitors
    Patent number: 7683097
    Abstract: The present invention provides compounds that are effective against inhibiting topoisomerase (i.e., topoisomerase I and/or topoisomerase II). These compounds are used for treating cell-proliferative disorders. In some instances, these compounds have anticancer activity, e.g., against multi-drug resistant cancers.
    Type: Grant
    Filed: May 25, 2005
    Date of Patent: March 23, 2010
    Assignee: Propharmacon Inc.
    Inventors: Martin A. Murphy, John Robert Schullek, John S. Ward, Gary C. Look, Brian Siesel
  • Collagenase-1 and stromelysin-1 inhibitors, pharmaceutical compositions comprising same and methods of their use
    Patent number: 6271232
    Abstract: Novel inhibitors of metalloproteases, in particular collagenase-1 and stromelysin-1, are disclosed. Such compounds are useful in pharmaceutical compositions and methods for treating or controlling disease states or conditions which involve tissue breakdown, such as rheumatoid arthritis.
    Type: Grant
    Filed: July 9, 1999
    Date of Patent: August 7, 2001
    Assignee: Affymax Technologies, N.V.
    Inventors: David Campbell, Gary C. Look, Anna Katrin Szardenings, Dinesh V. Patel
  • Inhibitors of metalloproteases pharmaceutical compositions comprising same and methods of their use
    Patent number: 5990112
    Abstract: Novel inhibitors of metalloproteases are disclosed. Such compounds are useful in pharmaceutical compositions and methods for treating or controlling disease states or conditions which involve tissue breakdown, such as rheumatoid arthritis.
    Type: Grant
    Filed: June 18, 1996
    Date of Patent: November 23, 1999
    Assignee: Affymax Technologies N.V.
    Inventors: David Campbell, Gary C. Look, Anna Katrin Szardenings, Dinesh V. Patel
  • Collagenase-1 and stromelysin-1 inhibitors, pharmaceutical compositions comprising same and methods of their use
    Patent number: 5932579
    Abstract: Novel inhibitors of metalloproteases, in particular collagenase-1 and stromelysin-1, are disclosed. Such compounds are useful in pharmaceutical compositions and methods for treating or controlling disease states or conditions which involve tissue breakdown, such as rheumatoid arthritis.
    Type: Grant
    Filed: June 18, 1996
    Date of Patent: August 3, 1999
    Assignee: Affymax Technologies N.V.
    Inventors: David Campbell, Gary C. Look, Anna Katrin Szardenings, Dinesh V. Patel
  • Enzymatic process for producing a galactosyl.beta.1,3glycal disaccaride using .beta.-galactosidase
    Patent number: 5403726
    Abstract: An enzymatic process is disclosed for the preparation of galactosyl.beta.1,3glycal disaccharides such as Gal.beta.1,3Glucal, an intermediate useful in Le.sup.a preparation and an inhibitor of .beta.-galactosidase. The process utilizes .beta.-galactosidase, an enzyme usually used for bond breaking, to form a bond between a galactoside and a glucal such as glycal, a 6-O--C.sub.1 -C.sub.6 acylglucal or 6-O--C.sub.1 -C.sub.6 acetylgalactal.
    Type: Grant
    Filed: July 16, 1992
    Date of Patent: April 4, 1995
    Assignee: The Scripps Research Institute
    Inventors: Chi-Huey Wong, Gary C. Look